Skip to content
2000
Volume 33, Issue 6
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Multiple myeloma (MM) is the second most common hematologic malignancy, accounting for approximately 10% of all hematological cases, with higher morbidity and mortality.

Objective

This study aimed to investigate the clonal evolutionary characteristics to identify novel prognostic biomarkers associated with extramedullary progression in MM.

Methods

We downloaded transcriptomic profiles and single-cell microarray (scRNA-seq) data from public databases. Then, we used the LASSO method to develop a prognostic signature and validated its efficacy using external MM cohorts. We evaluated the differences in the immune microenvironment and drug sensitivity (IC) between the different risk score groups. scRNA-seq analysis identified key cell types through AUCell scores, cell communication, and differentiation trajectory analyses.

Results

In total, 126 DEGs were identified as crucial genes associated with extramedullary and intramedullary MM. After LASSO analysis, seven signature genes were selected to develop a risk score model, and high-risk patients showed worse outcomes. Subsequently, the nomogram incorporating age, albumin, b2m, LDH, and RiskScore predicted 1-, 3-, and 5-year outcomes with high AUCs. Immune analyses showed that 25 immune cell types, 35 immune checkpoints, 27 chemokines, 20 MHC molecules, and 14 receptor-related genes differed significantly between the two risk groups. We also identified 116 drugs (roscovitine and JNK inhibitor VIII) with significantly different IC values between the two risk groups. CD4+ T cells exhibited the highest signature gene activity. CellChat analysis demonstrated enhanced communication between CD4+, NK, and CD8+ T cells.

Conclusion

Our study has proposed a risk score model based on seven identified signature genes for MM prognosis and revealed CD4+ T cells to be a major immune cell type associated with MM progression, contributing to personalized treatment decision-making and precise risk stratification of MM.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673352012250414100227
2025-05-05
2026-02-26

  • From This Site

    /content/journals/cmc/10.2174/0109298673352012250414100227
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HuangJ. ChanS.C. LokV. ZhangL. Lucero-PrisnoD.E.III XuW. ZhengZ.J. ElcarteE. WithersM. WongM.C.S. The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends.Lancet Haematol.202299e670e67710.1016/S2352‑3026(22)00165‑X35843248
     [Google Scholar]
  2. ParikhR.H. LonialS. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.CA Cancer J. Clin.202373327528510.3322/caac.2177136627265
     [Google Scholar]
  3. CowanA.J. GreenD.J. KwokM. LeeS. CoffeyD.G. HolmbergL.A. TuazonS. GopalA.K. LibbyE.N. Diagnosis and management of multiple myeloma.JAMA2022327546447710.1001/jama.2022.000335103762
     [Google Scholar]
  4. JosephN.S. KaufmanJ.L. DhodapkarM.V. HofmeisterC.C. AlmaulaD.K. HeffnerL.T. GuptaV.A. BoiseL.H. LonialS. NookaA.K. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma.J. Clin. Oncol.202038171928193710.1200/JCO.19.0251532298201
     [Google Scholar]
  5. GarfallA.L. New biological therapies for multiple myeloma.Annu. Rev. Med.2024751132910.1146/annurev‑med‑050522‑03381537729027
     [Google Scholar]
  6. HolsteinS.A. GrantS.J. WildesT.M. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: Moving into the future.J. Clin. Oncol.202341274416442910.1200/JCO.23.0051237471687
     [Google Scholar]
  7. DimaD. AbdallahA.O. DavisJ.A. AwadaH. GoelU. RashidA. DeJarnetteS. AnwerF. ShuneL. RazaS. MahmoudjafariZ. WilliamsL. FaimanB. McGuirkJ.P. SauterC.S. AhmedN. KhouriJ. HashmiH. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy.Blood Cancer J.20241419010.1038/s41408‑024‑01068‑w38821914
     [Google Scholar]
  8. BladéJ. BeksacM. CaersJ. JurczyszynA. von Lilienfeld-ToalM. MoreauP. RascheL. RosiñolL. UsmaniS.Z. ZamagniE. RichardsonP. Extramedullary disease in multiple myeloma: A systematic literature review.Blood Cancer J.20221234510.1038/s41408‑022‑00643‑335314675
     [Google Scholar]
  9. BhutaniM. FoureauD.M. AtrashS. VoorheesP.M. UsmaniS.Z. Extramedullary multiple myeloma.Leukemia202034112010.1038/s41375‑019‑0660‑031776467
     [Google Scholar]
  10. RyuD. KimS.J. HongY. JoA. KimN. KimH.J. LeeH.O. KimK. ParkW.Y. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion.Clin. Cancer Res.202026493594410.1158/1078‑0432.CCR‑19‑069431558476
     [Google Scholar]
  11. XiaY. ShiY. ChenZ. ZhangJ. ZhuY. GuoR. ZhangR. ShiQ. LiJ. ChenL. Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma.Chin. Med. J.2022135202500250210.1097/CM9.000000000000235136583869
     [Google Scholar]
  12. JelinekT. ZihalaD. SevcikovaT. Anilkumar SitharaA. KapustovaV. SahinbegovicH. VenglarO. MuronovaL. BroskevicovaL. NenarokovS. BilekD. PopkovaT. PlonkovaH. VranaJ. ZidlikV. HurnikP. HavelM. HrdinkaM. ChyraZ. StracquadanioG. SimicekM. HajekR. Beyond the marrow: Insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Leukemia20243861323133310.1038/s41375‑024‑02206‑w38493239
     [Google Scholar]
  13. ChariA. MinnemaM.C. BerdejaJ.G. OriolA. van de DonkN.W.C.J. Rodríguez-OteroP. AskariE. MateosM.V. CostaL.J. CaersJ. VeronaR. GirgisS. YangS. GoldsmithR.B. YaoX. PillarisettiK. HilderB.W. RussellJ. GoldbergJ.D. KrishnanA. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma.N. Engl. J. Med.2022387242232224410.1056/NEJMoa220459136507686
     [Google Scholar]
  14. JelinekT. SevcikovaT. ZihalaD. PopkovaT. KapustovaV. BroskevicovaL. CapkovaL. RihovaL. BezdekovaR. SevcikovaS. ZidlikV. HavelM. PlonkovaH. JungovaA. MinarikJ. StorkM. PourL. PavlicekP. SpickaI. MaisnarV. RadochaJ. SimicekM. HajekR. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.Leukemia202236128829110.1038/s41375‑021‑01343‑w34247197
     [Google Scholar]
  15. MoreauP. GarfallA.L. van de DonkN.W.C.J. NahiH. San-MiguelJ.F. OriolA. NookaA.K. MartinT. RosinolL. ChariA. KarlinL. BenboubkerL. MateosM.V. BahlisN. PopatR. BesemerB. Martínez-LópezJ. SidanaS. DelforgeM. PeiL. TrancucciD. VeronaR. GirgisS. LinS.X.W. OlyslagerY. JaffeM. UhlarC. StephensonT. Van RampelberghR. BanerjeeA. GoldbergJ.D. KobosR. KrishnanA. UsmaniS.Z. Teclistamab in relapsed or refractory multiple myeloma.N. Engl. J. Med.2022387649550510.1056/NEJMoa220347835661166
     [Google Scholar]
  16. López-CorralL. CorcheteL.A. SarasqueteM.E. MateosM.V. García-SanzR. FermiñánE. LahuertaJ.J. BladéJ. OriolA. TeruelA.I. MartinoM.L. HernándezJ. Hernández-RivasJ.M. BurguilloF.J. San MiguelJ.F. GutiérrezN.C. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.Haematologica20149981365137210.3324/haematol.2013.08780924816239
     [Google Scholar]
  17. DanzigerS.A. McConnellM. GockleyJ. YoungM.H. RosenthalA. SchmitzF. ReissD.J. FarmerP. AlapatD.V. SinghA. AshbyC. BauerM. RenY. SmithK. CoutoS.S. van RheeF. DaviesF. ZangariM. PettyN. OrlowskiR.Z. DhodapkarM.V. CopelandW.B. FoxB. HoeringA. FitchA. NewhallK. BarlogieB. TrotterM.W.B. HershbergR.M. WalkerB.A. DervanA.P. RatushnyA.V. MorganG.J. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the total therapy clinical trials.PLoS Med.20201711e100332310.1371/journal.pmed.100332333147277
     [Google Scholar]
  18. ZhongL. HaoP. ZhangQ. JiangT. LiH. XiaoJ. LiC. LuoL. XieC. HuJ. WangL. LiuY. ShiY. ZhangW. GongB. Revised international staging system (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).eLife202211e7534010.7554/eLife.7534036315425
     [Google Scholar]
  19. RitchieM.E. PhipsonB. WuD. HuY. LawC.W. ShiW. SmythG.K. limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic Acids Res.2015437e4710.1093/nar/gkv00725605792
     [Google Scholar]
  20. GuZ. EilsR. SchlesnerM. Complex heatmaps reveal patterns and correlations in multidimensional genomic data.Bioinformatics201632182847284910.1093/bioinformatics/btw31327207943
     [Google Scholar]
  21. ChenH. BoutrosP.C.J.B.b. VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R.BMC Bioinformatics2011123510.1186/1471‑2105‑12‑35
     [Google Scholar]
  22. YuG. WangL.G. HanY. HeQ.Y. clusterProfiler: An R package for comparing biological themes among gene clusters.OMICS201216528428710.1089/omi.2011.011822455463
     [Google Scholar]
  23. VillanuevaR.A.M. ChenZ.J. ggplot2: Elegant graphics for data analysis.Measurement201917316016710.1080/15366367.2019.1565254
     [Google Scholar]
  24. YangL. QuQ. HaoZ. ShaK. LiZ. LiS. Powerful identification of large quantitative trait loci using genome-wide R/glmnet-based regression.J. Hered.2022113447247810.1093/jhered/esac00635134967
     [Google Scholar]
  25. LiC. ZhangY. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer.BMC Med. Genomics202316115810.1186/s12920‑023‑01590‑z37422644
     [Google Scholar]
  26. YangH. WangK. LiB. LiS. LiY. YuanL. The prognostic role of blood inflammatory biomarkers and EGFR mutation status in stage IIIA/N2 non-small cell lung cancer patients treated with trimodality therapy.Front. Oncol.20211170704110.3389/fonc.2021.70704134917497
     [Google Scholar]
  27. NorbertW. In Extrapolation, Interpolation, and Smoothing of Stationary Time Series: With Engineering Applications.MIT Press1964129148
     [Google Scholar]
  28. LiberzonA. SubramanianA. PinchbackR. ThorvaldsdóttirH. TamayoP. MesirovJ.P. Molecular signatures database (MSigDB) 3.0.Bioinformatics201127121739174010.1093/bioinformatics/btr26021546393
     [Google Scholar]
  29. CharoentongP. FinotelloF. AngelovaM. MayerC. EfremovaM. RiederD. HacklH. TrajanoskiZ. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep.201718124826210.1016/j.celrep.2016.12.01928052254
     [Google Scholar]
  30. Suárez-FariñasM. LowesM.A. ZabaL.C. KruegerJ.G. Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA).PLoS One201054e1024710.1371/journal.pone.001024720422035
     [Google Scholar]
  31. GeeleherP. CoxN. HuangR.S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels.PLoS One201499e10746810.1371/journal.pone.010746825229481
     [Google Scholar]
  32. WangH. ZhaoY. ZhangC. LiM. JiangC. LiY. Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas.PLoS One201492e8978210.1371/journal.pone.008978224587032
     [Google Scholar]
  33. JinS. Guerrero-JuarezC.F. ZhangL. ChangI. RamosR. KuanC.H. MyungP. PlikusM.V. NieQ. Inference and analysis of cell-cell communication using CellChat.Nat. Commun.2021121108810.1038/s41467‑021‑21246‑933597522
     [Google Scholar]
  34. QiuX. HillA. PackerJ. LinD. MaY.A. TrapnellC. Single-cell mRNA quantification and differential analysis with Census.Nat. Methods201714330931510.1038/nmeth.415028114287
     [Google Scholar]
  35. KassambaraA.J.R.p.v. ggpubr: ‘ggplot2’ Based publication ready plots.2018Available from: https://rpkgs.datanovia.com/ggpubr/
  36. TayR.E. RichardsonE.K. TohH.C. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms.Cancer Gene Ther.2021281-251710.1038/s41417‑020‑0183‑x32457487
     [Google Scholar]
  37. BorstJ. AhrendsT. BąbałaN. MeliefC.J.M. KastenmüllerW. CD4+ T cell help in cancer immunology and immunotherapy.Nat. Rev. Immunol.2018181063564710.1038/s41577‑018‑0044‑030057419
     [Google Scholar]
  38. KennedyR. CelisE. Multiple roles for CD4+ T cells in anti-tumor immune responses.Immunol. Rev.2008222112914410.1111/j.1600‑065X.2008.00616.x18363998
     [Google Scholar]
  39. PrabhalaR.H. PelluruD. FulcinitiM. PrabhalaH.K. NanjappaP. SongW. PaiC. AminS. TaiY.T. RichardsonP.G. GhobrialI.M. TreonS.P. DaleyJ.F. AndersonK.C. KutokJ.L. MunshiN.C. Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.Blood2010115265385539210.1182/blood‑2009‑10‑24666020395418
     [Google Scholar]
  40. BryantC. SuenH. BrownR. YangS. FavaloroJ. AkliluE. GibsonJ. HoP.J. IlandH. FrommP. WoodlandN. NassifN. HartD. JoshuaD.E. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.Blood Cancer J.201339e14810.1038/bcj.2013.3424036947
     [Google Scholar]
  41. PrabhalaR.H. NeriP. BaeJ.E. TassoneP. ShammasM.A. AllamC.K. DaleyJ.F. ChauhanD. BlanchardE. ThatteH.S. AndersonK.C. MunshiN.C. Dysfunctional T regulatory cells in multiple myeloma.Blood2006107130130410.1182/blood‑2005‑08‑310116150935
     [Google Scholar]
  42. BrimnesM.K. VangstedA.J. KnudsenL.M. GimsingP. GangA.O. JohnsenH.E. SvaneI.M. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.Scand. J. Immunol.201072654054710.1111/j.1365‑3083.2010.02463.x21044128
     [Google Scholar]
  43. SpanoudakisE. HuM. NareshK. TerposE. MeloV. ReidA. KotsianidisI. AbdallaS. RahemtullaA. KaradimitrisA. Regulation of multiple myeloma survival and progression by CD1d.Blood2009113112498250710.1182/blood‑2008‑06‑16128119056691
     [Google Scholar]
  44. GudgeonN. GilesH. BishopE.L. Fulton-WardT. Escribano-GonzalezC. MunfordH. James-BottA. FosterK. KarimF. JayawardanaD. MahmoodA. CribbsA.P. TennantD.A. BasuS. PrattG. DimeloeS. Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma.Blood Adv.20237206035604710.1182/bloodadvances.202300989037276076
     [Google Scholar]
  45. JiangY. YaoJ. YaoZ. HuangY. LiZ. FanZ. ZhouY. LiG. LiZ. XuB. CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity.Med. Oncol.202340925310.1007/s12032‑023‑02123‑537498412
     [Google Scholar]
  46. LedergorG. FanZ. WuK. McCarthyE. Hyrenius-WittstenA. StarzinskiA. ChangH. BridgeM. KwekS. CheungA. BylsmaS. HansenE. WolfJ. WongS. ShahN. RoybalK.T. MartinT. YeC.J. FongL. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.Blood Adv.20248133562357510.1182/bloodadvances.202301241638574299
     [Google Scholar]
  47. CohenM. GiladiA. BarboyO. HamonP. LiB. ZadaM. Gurevich-ShapiroA. BeccariaC.G. DavidE. MaierB.B. BuckupM. KamerI. DeczkowskaA. Le BerichelJ. BarJ. IannaconeM. TanayA. MeradM. AmitI. The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.Nat. Cancer20223330331710.1038/s43018‑022‑00338‑535241835
     [Google Scholar]
  48. ChongA.S.F. BoussyI.A. JiangX.L. LamasM. GrafL.H.Jr. CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity.Cell. Immunol.199415719210510.1006/cimm.1994.12087518755
     [Google Scholar]
  49. CrozatK. EidenschenkC. JaegerB.N. KrebsP. GuiaS. BeutlerB. VivierE. UgoliniS. Impact of β2 integrin deficiency on mouse natural killer cell development and function.Blood2011117102874288210.1182/blood‑2010‑10‑31545721239699
     [Google Scholar]
  50. WangT. MaF. QianH. Defueling the cancer: ATP synthase as an emerging target in cancer therapy.Mol. Ther. Oncolytics202123829510.1016/j.omto.2021.08.01534703878
     [Google Scholar]
  51. PatrónL.A. NagatomoK. EvesD.T. ImadM. YoungK. TorvundM. GuoX. RogersG.C. ZinsmaierK.E. Cul4 ubiquitin ligase cofactor DCAF12 promotes neurotransmitter release and homeostatic plasticity.J. Cell Biol.20192183993101010.1083/jcb.20180509930670470
     [Google Scholar]
  52. YangY. WangS. LiJ. QiS. ZhangD. CUL4A as a marker and potential therapeutic target in multiple myeloma.Tumour Biol.201739710.1177/101042831770392328677427
     [Google Scholar]
  53. BarankiewiczJ. Szumera-CiećkiewiczA. Salomon-PerzyńskiA. WieszczyP. MalendaA. GarbiczF. Prochorec-SobieszekM. Misiewicz-KrzemińskaI. JuszczyńskiP. Lech-MarańdaE. The CRBN, CUL4A and DDB1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients.J. Clin. Med.20211012268310.3390/jcm1012268334207079
     [Google Scholar]
  54. CarvalhoF. CostaE.T. CamargoA.A. GregorioJ.C. MasottiC. AndradeV.C.C. StraussB.E. CaballeroO.L. AtanackovicD. ColleoniG.W.B. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.PLoS One2011611e2770710.1371/journal.pone.002770722110734
     [Google Scholar]
  55. de CarvalhoF. AlvesV.L.F. BragaW.M.T. XavierC.V.Jr ColleoniG.W.B. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.Cancer Immunol. Immunother.201362119119510.1007/s00262‑012‑1376‑423180015
     [Google Scholar]
  56. LinJ.X. LeonardW.J. The common cytokine receptor γ chain family of cytokines.Cold Spring Harb. Perspect. Biol.2018109a02844910.1101/cshperspect.a02844929038115
     [Google Scholar]
  57. BayerA.L. LeeJ.Y. de la BarreraA. SurhC.D. MalekT.R. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells.J. Immunol.20081811225234
     [Google Scholar]
  58. VangK.B. YangJ. MahmudS.A. BurchillM.A. VegoeA.L. FarrarM.A. IL-2, -7, and -15, but not thymic stromal lymphopoietin, redundantly govern CD4+Foxp3+ regulatory T cell development.J. Immunol.2008181532853290
     [Google Scholar]
  59. BębnowskaD. HrynkiewiczR. GrywalskaE. PasiarskiM. Sosnowska-PasiarskaB. Smarz-WidelskaI. GóźdźS. RolińskiJ. Niedźwiedzka-RystwejP. Immunological prognostic factors in multiple myeloma.Int. J. Mol. Sci.2021227358710.3390/ijms2207358733808304
     [Google Scholar]
  60. WangL. WangJ. LiuW. WangW. WangH. ChenX. GengQ. LuY. XiaZ. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.Ann. Hematol.201796122079208810.1007/s00277‑017‑3125‑428871325
     [Google Scholar]
  61. MuhammadS. FanT. HaiY. GaoY. HeJ. Reigniting hope in cancer treatment: The promise and pitfalls of IL-2 and IL-2R targeting strategies.Mol. Cancer202322112110.1186/s12943‑023‑01826‑737516849
     [Google Scholar]
  62. HessD. IversenK.F. MateosM.-V. PabstT. RosiñolL. KovacikovaJ. SchnetzlerS.J. OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.JCO20234116_supplTPS806810.1200/JCO.2023.41.16_suppl.TPS8068
     [Google Scholar]
  63. SongM.J. JungC.K. ParkC.H. HurW. ChoiJ.E. BaeS.H. ChoiJ.Y. ChoiS.W. HanN.I. YoonS.K. RPL36 as a prognostic marker in hepatocellular carcinoma.Pathol. Int.2011611163864410.1111/j.1440‑1827.2011.02716.x22029674
     [Google Scholar]
  64. CaoX. KhitunA. LuoY. NaZ. PhoodokmaiT. SappakhawK. OlatunjiE. UttamapinantC. SlavoffS.A. Alt-RPL36 downregulates the PI3K-AKT-mTOR signaling pathway by interacting with TMEM24.Nat. Commun.202112150810.1038/s41467‑020‑20841‑633479206
     [Google Scholar]
  65. WangZ. LiJ. LongX. JiaoL. ZhouM. WuK. MRPS16 facilitates tumor progression via the PI3K/AKT/Snail signaling axis.J. Cancer20201182032204310.7150/jca.3967132127931
     [Google Scholar]
  66. LiaoY. ShaoZ. LiuY. XiaX. DengY. YuC. SunW. KongW. HeX. LiuF. GuoZ. ChenG. TangD. GanH. LiuJ. HuangH. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells.J. Exp. Clin. Cancer Res.202140120110.1186/s13046‑021‑02008‑334154657
     [Google Scholar]
  67. RajeN. KumarS. HideshimaT. RoccaroA. IshitsukaK. YasuiH. ShiraishiN. ChauhanD. MunshiN.C. GreenS.R. AndersonK.C. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.Blood200510631042104710.1182/blood‑2005‑01‑032015827128
     [Google Scholar]
  68. MacCallumD.E. MelvilleJ. FrameS. WattK. AndersonS. Gianella-BorradoriA. LaneD.P. GreenS.R. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.Cancer Res.200565125399540710.1158/0008‑5472.CAN‑05‑023315958589
     [Google Scholar]
  69. HideshimaT. HayashiT. ChauhanD. AkiyamaM. RichardsonP. AndersonK. Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines.Oncogene200322548797880110.1038/sj.onc.120691914647474
     [Google Scholar]
  70. CollaS. ZhanF. YaccobyS. EpsteinJ. BarlogieB. ShaughnessyJ.D.Jr RegulatesJ.N.K. JNK regulates DKK1 expression in multiple myeloma cells.Blood2006108113411341110.1182/blood.V108.11.3411.341117255354
     [Google Scholar]
  71. SalimiA. SchroederK.M. Schemionek-ReindersM. VieriM. MaletzkeS. GezerD. MasoulehB.K. AppelmannI. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.BMC Cancer202222173510.1186/s12885‑022‑09775‑y35790913
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673352012250414100227
Loading
Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma
Curr. Med. Chem. 33, 1190 (2026); https://doi.org/10.2174/0109298673352012250414100227
/content/journals/cmc/10.2174/0109298673352012250414100227
/content/journals/cmc/10.2174/0109298673352012250414100227
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): CD8+ T cells; extramedullary; Multiple myeloma; plasma cells; prognosis; single-cell profile

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test